Clostridioides difficile infection (CDI) remains a significant public health challenge worldwide, especially in healthcare settings. Despite advancements in diagnosis and treatment, the Clostridioides difficile infection treatment market is characterized by persistent therapeutic limitations, particularly the high recurrence of Clostridioides difficile infection (rCDI), which affects 25–45% of patients, depending on the severity and history of prior episodes.
From Legacy Antibiotics to Fidaxomicin: A Decade of CDI Evolution
The treatment landscape for CDI has undergone significant changes over the past decade. Once dominated by metronidazole and vancomycin, the ...
